ArticleThe neuroradiology journal2024
Safety and efficacy of Surpass Evolve Flow diverter for intracranial aneurysms: A study of 116 patients.
Article in The neuroradiology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparative outcomes of surpass streamline and evolve flow diverters in intracranial aneurysms: a comprehensive systematic review and meta-analysis of location, size, and morphology.Neurosurgical review · 2026Pooled it
- Flow diverter treatment for saccular unruptured intracranial aneurysms: A systematic review focussing on study quality and initial outcomes.European stroke journal · 2026Pooled it
- Efficacy and safety of surpass evolve flow diverters: A systematic review and meta-analysis.Clinical neurology and neurosurgery · 2025Pooled it
- Real-Time AI-Generated Guidewire-Out-of-View Notifications in Diagnostic Cerebral Angiography: Higher Observed Rates Among Trainees.Clinical neuroradiology · 2026Article
- Early experience with the Surpass Elite flow diverter for unruptured intracranial aneurysms.Neuroradiology · 2026Article
- Ticagrelor use in ruptured aneurysms: A retrospective cohort study.The neuroradiology journal · 2026Article
- Treatment outcome of flow-diversion with Surpass Evolve stent for unruptured intracranial aneurysms: Predictors of poor occlusion.Journal of cerebrovascular and endovascular neurosurgery · 2026Article
- Intra-Distal Access Catheter Deployment of the Surpass Evolve Device: A Novel Technique to Prevent Advancement of the Delivery Wire: A Case Report and Literature Review.Journal of neuroendovascular therapy · 2026Article
- Flow diverter treatment for saccular unruptured intracranial aneurysms: A systematic review focussing on study quality and initial outcomes.European stroke journal · 2025Article
- Lattice Flow Diverter for the Treatment of Unruptured Intracranial Aneurysms: A Retrospective Study.Cardiovascular and interventional radiology · 2025Article
- Use of the Tubridge flow diverter in the treatment of intracranial aneurysms: a single center experience.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeFlow diverter embolization is a recognized method for treating intracranial aneurysms. This study evaluates the safety and efficacy of the Surpass Evolve flow diverter in treating intracranial aneurysm. MATERIAL AND
methodsFrom May 2019 to June 2022, our center prospectively enrolled patients presenting with both ruptured and unruptured intracranial aneurysms. We assessed aneurysm occlusion, along with the occurrence of ischemic and hemorrhagic complications, and mortality at 6-months. The 3-month occlusion rate was determined using MR angiography, while the 6-month occlusion rate employed the O'Kelly-Marotta (OKM) grading scale on DSA.
resultsA total of 116 patients with 120 aneurysms received treatment with the Surpass Evolve device. The average aneurysm size was 6.6 mm (range: 2-30 mm). All patients were administered two loading doses of ticagrelor (180 mg) one day before the procedure and 2 h pre-embolization. A procedural complication occurred in one case, involving wire-related perforation of an M3 branch distant from the giant aneurysm; however, this evolved favorably. There were no reported deaths linked to the treatment. Permanent neurological deficits were observed in 3 (2.5%) patients, primarily due to early in-stent thrombosis. MR angiography results at 3 months indicated complete occlusion for 87 out of 115 (75.6%) monitored aneurysms. The 6-month DSA showed neck remnant or complete occlusion (OKM grade C or D) in 86 out of the 107 (80.4%) patients who underwent follow-up.
conclusionThe Surpass Evolve stands out as a reliable and effective flow diverter for the management of intracranial aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.